AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 AUG 28 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Enhancing the uptake of glioma tumor antigens by dendritic cells (DCs) through treatment with 7-hydroxystaurosporin increased survival of glioma tumor-bearing rats vaccinated with the glioma apoptotic body-pulsed DCs.
Noting that "tumoral apoptotic bodies may provide a potent source of antigen for delivery to antigen-presenting cells," Timothy F. Witham and colleagues at the University of Pittsburgh utilized the 9L glioma/Fischer rat model to test the ability of glioma apoptotic body-pulsed DCs to inhibit tumor growth.
The investigators pretreated 9L glioma cells for 72 or 96 hours with the protein kinase inhibitor 7-hydroxystaurosporin (UCN-01; 200-300 ng/mL) to stimulate apoptosis. Apoptosis occurred in 50% of the glioma tumor cells treated with DCs plus UCN-01-treated apoptic 9L compared with 3% of controls. The physical interaction of DCs with the apoptic glioma tumor cells was shown to be time-dependent by two-color flow cytometry.
In vivo studies revealed that rats with intracranial glioma tumors vaccinated with the glioma apoptotic body-pulsed DCs had a significantly longer survival compared with vehicle-treated control rats or animals that received DCs plus apoptic cells alone (p
None of the 16 control rats (0%) survived beyond 90 days compared with 6 of the 8 vaccinated rats (75%). Long-term survival occurred in 3 out of 4 surviving rats that underwent challenge with tumor cells delivered intracranially. Treatment with DCs plus nonapoptotic 9L glioma cells did ...
Source: HighBeam Research, Vaccine prepared with 7-hydroxystaurosporin found effective against...